First Amendment Challenge To DTC Rule Unlikely From Industry; For Now, It Is 'Comply With Context'
Executive Summary
DTC rule is a good fight to lose: it is a high-profile response to pricing, but will have a low impact – and is certainly a less painful solution than many of the alternatives.
You may also be interested in...
DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar
Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its drug pricing disclosures voluntary program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.
Trump Administration's Rx-Price-Disclosure Reg Sets Up Legal Fight With PhRMA
From kinds of ads targeted to agency that's issuing the reg, policy seems designed to withstand a court challenge.
US FDA Regulatory Affairs Reorg To Include Inspectors Trained In Real-World Evidence, Califf Says
The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”